Skip to main content
. 2022 Apr 25;306(6):2115–2122. doi: 10.1007/s00404-022-06558-5

Table 2.

Patient numbers according to the previous therapy

Therapy Yes No Exclusively
Any 174 (97.8%) 4 (2.2%)
Chemotherapy 165 (92.7%) 13 (7.3%) 17 (9.5%)
Endocrine therapy 135 (75.8%) 43 (24.2%) 8 (4.5%)
Anti-Her 2 30 (16.9%) 148 (83.1%) 0
Bevacizumab 38 (21.3%) 140 (78.7%) 0